Checkpoint TherapeuticsCKPT
CKPT
0
Funds holding %
of 7,390 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
440% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 5
106% more capital invested
Capital invested by funds: $17.2M [Q3] → $35.4M (+$18.2M) [Q4]
75% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 12
46% more funds holding
Funds holding: 46 [Q3] → 67 (+21) [Q4]
5.64% more ownership
Funds ownership: 17.33% [Q3] → 22.97% (+5.64%) [Q4]
3% less call options, than puts
Call options by funds: $1.6M | Put options by funds: $1.65M
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$4.10
1%
upside
Avg. target
$4.33
6%
upside
High target
$4.80
18%
upside
3 analyst ratings
1 positive
33%
2 neutral
67%
0 negative
0%
HC Wainwright & Co. Joseph Pantginis 21% 1-year accuracy 87 / 411 met price target | 1%upside $4.10 | Neutral Downgraded | 11 Mar 2025 |
Lake Street Thomas Flaten 44% 1-year accuracy 4 / 9 met price target | 1%upside $4.10 | Hold Downgraded | 10 Mar 2025 |
D. Boral Capital Jason Kolbert 31% 1-year accuracy 92 / 297 met price target | 18%upside $4.80 | Buy Maintained | 10 Mar 2025 |
Financial journalist opinion
Based on 7 articles about CKPT published over the past 30 days
Neutral
Business Wire
1 week ago
CHECKPOINT INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Checkpoint Therapeutics, Inc. - CKPT
NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Checkpoint Therapeutics, Inc. (NasdaqCM: CKPT) to Sun Pharmaceutical Industries Limited. Under the terms of the proposed transaction, shareholders of Checkpoint will receive $4.10 per share and a contingent value right for up to $0.70 per share on achievement of a milestone. KSF is seeking to determ.
Neutral
GlobeNewsWire
1 week ago
SHAREHOLDER ALERT: Kaskela Law LLC Announces Shareholder Investigation into Fairness of Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) Buyout Offer and Encourages Investors to Contact the Firm to Discuss Their Legal Rights and Options
PHILADELPHIA, March 13, 2025 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating the fairness of the recently announced buyout of Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT) shareholders.
Neutral
PRNewsWire
1 week ago
CKPT Merger Alert: Checkpoint Shareholders Seeking Money Should Contact Julie & Holleman Regarding Sale to Sun Pharma
NEW YORK , March 10, 2025 /PRNewswire/ -- Shareholder law firm Julie & Holleman LLP is investigating the proposed $4.10 per share sale of Checkpoint Therapeutics, Inc. (Nasdaq: CKPT) to Sun Pharmaceutical Industries, Inc. The firm is concerned about conflicts relating to Checkpoint's controlling shareholder, Fortress Biotech, Inc. (Nasdaq: FBIO), which has secured special benefits in the deal. For a free consultation, or to learn more, contact partner W.
Positive
Proactive Investors
1 week ago
Checkpoint Therapeutics shares pop on acquisition by Sun Pharma
Checkpoint Therapeutics (NASDAQ:CKPT) shares added more than 60% after it was revealed the immunology and targeted oncology firm will be acquired by Sun Pharmaceutical Industries. Under the agreement, Sun Pharma will acquire Checkpoint for $4.10 per share in cash, representing up to $355 million in upfront payments.
Neutral
Business Wire
1 week ago
CKPT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Checkpoint Therapeutics, Inc. Is Fair to Shareholders
NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) to Sun Pharmaceutical Industries Limited for $4.10 per share and a contingent value right for up to $0.70 per share on achievement of a milestone is fair to Checkpoint shareholders. Halper Sadeh encourages Checkpoint shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (21.
Neutral
Business Wire
1 week ago
Shareholder Alert: The Ademi Firm Investigates Whether Checkpoint Therapeutics, Inc. is Obtaining a Fair Price for Its Public Shareholders
MILWAUKEE--(BUSINESS WIRE)--The Ademi Firm is investigating Checkpoint (Nasdaq: CKPT) for possible breaches of fiduciary duty and other violations of law in its transaction with Sun Pharma. Click here to learn how to join our investigation and obtain additional information or contact us at gademi@ademilaw.com or toll-free: 866-264-3995. There is no cost or obligation to you. In the transaction, Checkpoint stockholders will receive an upfront cash payment of only $4.10, without interest, and a n.
Neutral
PRNewsWire
1 week ago
Sun Pharma to Acquire Checkpoint Therapeutics
Will add UNLOXCYT™ (cosibelimab-ipdl), the first and only FDA-approved anti-PD-L1 treatment for metastatic or locally advanced cutaneous squamous cell carcinoma (cSCC) to Sun Pharma's global onco-derm franchise Will leverage Sun Pharma's global presence toaccelerate patient access to UNLOXCYT™ (cosibelimab-ipdl) Upfront cash payment of $4.10 per share of common stock,representing aggregate upfront consideration of up to $355 million Stockholders will also receive a contingent value right forup to $0.70 per share on achievement of a milestone Acquisition is subject to approval by Checkpoint's stockholdersand other customary closing conditions MUMBAI, India and WALTHAM, Mass., March 9, 2025 /PRNewswire/ -- Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715 (together with its subsidiaries and/or associated companies, "Sun Pharma")) and Checkpoint Therapeutics, Inc. (Nasdaq: CKPT) ("Checkpoint") today announced that they have entered into an agreement by which Sun Pharma will acquire Checkpoint, an immunotherapy and targeted oncology company.
Positive
Seeking Alpha
3 months ago
Checkpoint Therapeutics: Updating My Strategy After Unloxcyt's Approval
Checkpoint Therapeutics, Inc. received FDA approval for Unloxcyt, the first PD-L1 drug for advanced cSCC, with strong clinical results and a market-disruptive pricing strategy. Despite mixed investor reactions, Unloxcyt's potential $1.6B peak sales and competitive pricing could make it a transformative player in the cSCC market. Risks include high competition, commercialization costs, and potential IP challenges, but Checkpoint's strategic partnerships and marketing are crucial for success.
Neutral
GlobeNewsWire
3 months ago
Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl)
UNLOXCYT is the first and only FDA-approved anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma UNLOXCYT is the first and only FDA-approved anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma
Positive
Seeking Alpha
4 months ago
Checkpoint Therapeutics: Preparing For Cosibelimab's Upcoming PDUFA Date
Checkpoint Therapeutics, Inc.'s cosibelimab shows promising efficacy and safety in treating cSCC, with a high tumor occupancy rate and strong clinical data. The upcoming PDUFA date on December 28th is crucial, with potential FDA approval driving significant market growth and revenue projections. Despite competitive pressures and financial risks, cosibelimab's unique mechanism and strong IP position offer substantial market opportunities in cSCC and beyond.
Charts implemented using Lightweight Charts™